Current Report Filing (8-k)
September 28 2016 - 3:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 23, 2016
NEUROTROPE, INC.
(Exact name of registrant as specified
in its charter)
Nevada
(State or other
jurisdiction of
incorporation)
|
000-55275
(Commission File
Number)
|
46-3522381
(IRS Employer
Identification
Number)
|
205 East 42nd St- 20th Fl.
New York NY 10017
(Address of principal executive offices,
including ZIP code)
(973) 242-0005
(Registrant’s telephone number,
including area code)
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02
|
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers;
Compensatory Arrangements of Certain Officers.
|
(c) On
September 28, 2016, Neurotrope, Inc. (the “Company”) announced that its board of directors (the “Board”)
appointed Dr. Daniel Alkon, M.D., as President of the Company, effective upon his separation from Blanchette Rockefeller Neurosciences
Institute (“BRNI”) on September 23, 2016. Dr. Alkon has served as the Company’s Chief Scientific Officer since
August 2013 and will continue to serve in such position following his appointment as President. Dr. Alkon’s compensation
as President has not yet been determined by the Compensation Committee of the Board.
Dr. Alkon, age 73, has been the founding
Scientific Director of BRNI since 1999. He received his undergraduate degree in chemistry in 1965 at the University of Pennsylvania.
After earning his M.D. at Cornell University and finishing an internship in medicine at the Mount Sinai Hospital in New York, he
joined the staff of the National Institutes of Health where during his 30 year career he became a Medical Director in the U.S.
Public Health Service at the National Institute of Neurological Disorders and Strokes and Chief of the Laboratory of Adaptive Systems. Dr. Alkon occupied the Toyota Chair in Neurodegenerative
diseases at BRNI from June 2006 until September 23, 2016. In this position, he and his team conducted multidisciplinary research
on the molecular and biophysical mechanisms of memory and memory dysfunction in psychiatric and neurological disorders, particularly
Alzheimer’s disease. From October 2000 until September 23, 2016, he was also a Professor at BRNI and a Professor of Neurology
at West Virginia University.
There are no arrangements or understandings
between Dr. Alkon and any other person pursuant to which he was selected as President of the Company. The Company is not aware
of any transaction in which Dr. Alkon has an interest requiring disclosure under Item 404(a) of Regulation S-K.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
NEUROTROPE, INC.
|
|
|
|
|
By:
|
/s/ Robert Weinstein
|
|
Name:
|
Robert Weinstein
|
|
Title:
|
Chief Financial Officer, Executive Vice President, Secretary and Treasurer
|
September 28, 2016
NextTrip (NASDAQ:NTRP)
Historical Stock Chart
From Mar 2024 to Apr 2024
NextTrip (NASDAQ:NTRP)
Historical Stock Chart
From Apr 2023 to Apr 2024
Real-Time news about NextTrip Inc (NASDAQ): 0 recent articles
More Neurotrope, Inc. News Articles